Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page.
Submission declined on 23 February 2026 by ChrysGalley (talk).
Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
Please do not remove reviewer comments or this notice until the submission is accepted.
Where to get help
If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.
To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.
Please note that if the issues are not fixed, the draft will be declined again.
Comment: This reads like an advert and seems to have been written by AI / LLM. It's not permitted to have direct links inside the article. Citebombs, WP:CITEBOMB are unhelpful to the reader. Language is promotional. Sources barely mention the laboratory, they refer to work done by the lab. This is not a summary of reliable sources. ChrysGalley (talk) 19:33, 23 February 2026 (UTC)
Health Systems Innovation Lab (HSIL) is a global research and training lab based at the Harvard T.H. Chan School of Public Health. It focuses on health system performance, health policy, and venture creation, and conducts its work across two interrelated streams—health systems and innovation—through a Harvard-based interdisciplinary team and an international collaborative network.
HSIL is internationally known for convening the world's largest health systems innovation event, the Annual Health Systems Innovation Hackathon,[1][2][3] which has generated a global venture pipeline dedicated to healthcare innovation and health system transformation, engaging more than 6,000 participants across 40 hubs in over 30 countries and incubating more than 100 ventures.
History and purpose
The lab was established under the leadership of Rifat Atun, Professor of Global Health Systems at Harvard University, Vice-Dean for Innovation and Non-Degree Education at the Harvard T.H. Chan School of Public Health.[4] He has been listed by Clarivate as a Highly Cited Researcher.[5][6] HSIL undertakes research, education, innovation, and translation activities to engage innovators, researchers, practitioners, and collaborators from government, the private sector, multilateral entities, and civil society to support high-value health systems and accelerate the diffusion of healthcare innovations.[7][8][9] Since 2021, HSIL has expanded into a global network of academic, policy, and industry partners spanning more than 60 countries.
Research and initiatives
HSIL’s work spans research, education, and translation activities:
Research – assessing health system performance, informing the implementation of health system innovations, and evaluating their impact to support progress toward high-value health systems. Risk Factors (e.g., Hypertension, Hypercholsterolemia) Diseases (e.g., Cancer, Cardiovascular Disease), Treatment Modalities (e.g., Surigery, Radiotherapy), Governance and Organization (e.g., National Cancer Control Plans), Financing (e.g., Innovative Financing and Fiscal Space), and Resource Management (e.g., Artificial Intelligence, Infrastrucure), among others, have been used as 'tracers' to analyse and measure system performance using an HSIL health systems analysis proprietary framework.[10][11][12][13][14][15][16][17][18][19]
Education – training students, researchers, policymakers, and practitioners to design, implement, and scale innovations to improve health system performance.[20][21][22]
Translation – translating research findings into policy and practice through support for innovation ecosystems, venture incubation, and advisory work with public and private entities.[23][24][25]
Health Systems Visualizer – a data observatory integrating health system data from multiple sources through interactive dashboards and AI-enabled analytics.
AI and Health Systems – research on algorithmic bias, regulation, and applications of artificial intelligence in health systems.[42][43][44]
Health Regulatory Senior Executive Leadership Program – led by the University of the Witwatersrand and Harvard T.H. Chan School of Public Health, aims to strengthen national regulatory authorities by enhancing the leadership and regulatory skills of national regulatory leaders.
Global collaboration and impact
HSIL researchers have produced more than 250 peer-reviewed publications, including work in The Lancet Oncology, The Lancet Global Health, BMJ Global Health, Nature Medicine, and The Lancet Digital Health.
HSIL coordinates a network of more than 40 hubs in over 30 countries, bringing together universities, ministries of health, civil-society organizations, and industry partners, including Microsoft, Novo Nordisk, Roche, Movement Health Foundation, and PATH.
More than 2,200 students and professionals have been trained through HSIL-affiliated courses and initiatives.
The lab has produced more than 25 policy reports and several global case studies to support reforms and venture-building activities in multiple countries.
^Atun, Rifat; Jaffray, David A.; Barton, Michael B.; Bray, Freddie; Baumann, Michael; Vikram, Bhadrasain; Hanna, Timothy P.; Knaul, Felicia M.; Lievens, Yolande; Lui, Tracey Y. M.; Milosevic, Michael; O'Sullivan, Brian; Rodin, Danielle L.; Rosenblatt, Eduardo; Van Dyk, Jacob (September 2015). "Expanding global access to radiotherapy". The Lancet. Oncology. 16 (10): 1153–1186. doi:10.1016/S1470-2045(15)00222-3. ISSN1474-5488. PMID26419354.
^Atun, Rifat; Knaul, Felicia Marie; Akachi, Yoko; Frenk, Julio (2012-12-08). "Innovative financing for health: what is truly innovative?". Lancet. 380 (9858): 2044–2049. doi:10.1016/S0140-6736(12)61460-3. ISSN1474-547X. PMID23102585.
^Atun, Rifat; Silva, Sachin; Knaul, Felicia M. (July 2017). "Innovative financing instruments for global health 2002-15: a systematic analysis". The Lancet. Global Health. 5 (7): e720–e726. doi:10.1016/S2214-109X(17)30198-5. ISSN2214-109X. PMID28619230.
^Ward, Zachary J.; Yeh, Jennifer M.; Reddy, Che L.; Gomber, Apoorva; Ross, Carlo; Rittiphairoj, Thanitsara; Manne-Goehler, Jennifer; Abdalla, Asmahan T.; Abdullah, Mohamed Ahmed; Ahmed, Abdurezak; Ankotche, Amos; Azad, Kishwar; Bahendeka, Silver; Baldé, Naby; Jain, Sunil M. (December 2022). "Estimating the total incidence of type 1 diabetes in children and adolescents aged 0-19 years from 1990 to 2050: a global simulation-based analysis". The Lancet. Diabetes & Endocrinology. 10 (12): 848–858. doi:10.1016/S2213-8587(22)00276-5. ISSN2213-8595. PMID36372070.
^Atun, Rifat; Sirohi, Bhawna; Reddy, Che; Gospodarowicz, Mary (November 2024). "Cancer control in the Commonwealth: a roadmap". The Lancet. Oncology. 25 (11): 1409–1412. doi:10.1016/S1470-2045(24)00591-6. ISSN1474-5488. PMID39427670.
^Ward, Zachary J.; Gaba, Qassi; Atun, Rifat (September 2024). "Cancer incidence and survival for 11 cancers in the Commonwealth: a simulation-based modelling study". The Lancet. Oncology. 25 (9): 1127–1134. doi:10.1016/S1470-2045(24)00336-X. ISSN1474-5488. PMID39127064.
^Reddy, Che L.; Sousa, Cecilia; Atun, Rifat (July 2025). "Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study". The Lancet. Oncology. 26 (7): 924–935. doi:10.1016/S1470-2045(25)00168-8. ISSN1474-5488. PMID40480237.
^Du, Anbang; Brede, Markus; McIntosh, Stuart A.; Zhang, Beining; Alem, Aminu O.; Borin, Gabriela; Cheah, Wilson; Copson, Ellen; Cutress, Ramsey I.; Folz, Anna; Helms, Emily T.; Memon, Zain; Olaniran, Olabiyi H.; Savva, Constantinos; Thomas, Edward (September 2025). "Public and philanthropic research funding, publications, and research networks for cancer in the Commonwealth and globally between 2016 and 2023: a comparative analysis". The Lancet. Oncology. 26 (9): e466–e476. doi:10.1016/S1470-2045(25)00338-9. ISSN1474-5488. PMID40907525.
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.
- Reliable sources include: reputable newspapers, magazines, academic journals, and books from respected publishers.
- Unacceptable sources include: personal blogs, social media, predatory publishers, most tabloids, and websites where anyone can contribute.
Replace any unreliable sources with high-quality sources. If you cannot find a reliable source for the material, it should be removed.